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Introduction
While tobacco use is widely known as a preventable 
cause of  premature death, its 
causal association to blindness 
is relatively unknown by smok-
ers. There is strong evidence that 
healthcare providers can positively 
affect tobacco cessation among 
their patients yet the voice of  op-
tometrists has been largely silent in 
the development of  tobacco cessa-
tion practice guidelines and health 
promotion strategies such as social 
marketing campaigns and graphic 
warning labels. Our research group 
has begun to examine Canadian 
optometrists’ key behaviors and 
attitudes toward patients who use 
tobacco. In this paper, we describe 
the level of  Canadian smokers’ 
knowledge of  the association of  
smoking with blindness and the 
ideas that Canadian optometrists 
and senior optometry students 
have about blindness-related 
graphic warning labels.
Tobacco Use & Health Impacts
Optometrists routinely encounter 
patients who have, do, or will 
smoke cigarettes. A 2008 report1 by 
the Propel Centre for Population 
Health Impact provides a compel-
ling average profile of  smoking 
among Canadians. An estimated 
17.9% of  Canadians over 14 years 
of  age smoked cigarettes1, with 
higher rates among males (20%) 
than females (16%). Among daily 
smokers, who were the majority 
(75.4%), almost 15 cigarettes were 
smoked daily. Provincial rates of  
smoking varied from a low of  
14.7% in British Columbia to a 
high of  20.8% in Manitoba with 
only two provinces having rates be-
low the national average (Ontario 
and British Columbia). The highest 
smoking prevalence (27%) existed 
among 20 to 24-year-olds and 
almost 19% of  students in grades 
5 to 9 had tried smoking. Accord-
ing to this report, two-thirds of  
smokers were seriously considering 
quitting in the next 6-months.
The leading causes of  premature 
death causally linked to smoking 
are coronary artery disease, lead-
ing to myocardial infarctions and 
cerebrovascular accidents, lung 
cancer, and chronic obstructive 
pulmonary disease.2 Public aware-
ness of  the negative consequences 
of  smoking is generally high for 
these diseases; for example, stud-
ies in Canada, the United States, 
the United Kingdom, Australia 
and Singapore have reported that 
most surveyed respondents knew 
that smoking causes lung cancer 
(>90%), heart disease (>83%) and 
stroke (>70%).3,4,5
Public knowledge that smoking 
causes sight threatening eye disease 
is generally much lower, typically 
less than 10%.3,6,7 Only one study4, 
which focused on eye care seeking 
smokers, found higher knowledge 
Most smokers are not aware that their tobacco use is a preventable cause of blindness.  Despite the 
important role optometrists can have impacting patient health choices; their voice has been largely 
silent in the development of tobacco cessation practice guidelines and health promotion strategies.  
In this study, we use the International Tobacco Control Policy Evaluation Project (ITC) Four Country 
Survey to describe the level of Canadian smokers’ knowledge of the association of smoking with 
blindness and we use focus groups to elicit ideas from Canadian optometrists and senior optometry 
students about blindness-related graphic warning labels.
Keywords: Smoking, blindness, graphic warning labels, optometry practice
ABstRACt
FEATURE ARTICLE
Vol 73  |  No 2 SpriNg/priNtempS  2011CaNad iaN  JourNal  of  optometr y  |  r eVue  CaNad i eNNe  d ’optométr i e 27
levels between 31 and 37%. This 
limited awareness is a significant 
problem because smoking has been 
shown to cause several eye diseases 
through ischemic and oxidative 
mechanisms.8 Smoking has been 
causally associated with age related 
macular degeneration9-13, nuclear 
and posterior subcapsular cata-
ract14-19, thyroid-associated ophthal-
mopathy20-22, optic neuropathies23-25 
and uveitis.26,27 While public 
knowledge of  smoking-induced 
eye disease is relatively low, fear of  
blindness is not. A study6 of  Brit-
ish youth (16-18 years old) found 
that, in comparison with lung 
cancer, heart disease and stroke, 
blindness was the least known 
but most feared consequence of  
smoking cigarettes. Interestingly, 
some healthcare practitioners (e.g., 
pharmacists) are finding that link-
ing smoking to blindness has been 
a successful part of  their tobacco 
cessation advice.28
The common occurrence of  
smoking, the limited public knowl-
edge of  smoking-associated eye 
disease, and the public’s fear of  
vision loss all provide important 
incentives for optometrists to en-
gage in patient education regarding 
tobacco prevention and cessation.
Health Practitioners Support-
ing Tobacco Prevention & 
Cessation
Addressing tobacco use in clinical 
practice is supported by an increas-
ing recognition that tobacco use 
and dependence is a preventable 
cause of  morbidity and mortality 
and healthcare providers can be 
effective facilitators of  tobacco 
cessation among their patients.29-34  
The U.S. Surgeon General’s 
web-site provides clinical prac-
tice guidelines, entitled, Treating 
Tobacco Use and Dependence: 
2008 Update.35 This document was 
developed by stakeholders includ-
ing those from medicine, nursing, 
dentistry, pharmacy, epidemiol-
ogy, public health, and psychol-
ogy. Unfortunately, optometry is 
notably missing as a stakeholder 
informant or as an identified user 
of  the document. Optometry has 
also yet to be a stakeholder in the 
development of  Health Canada’s 
graphic warning labels for tobacco 
products. Graphic warning labels 
can be a useful tobacco prevention 
and cessation strategy, either on 
cigarette packages or posters.  For 
example, they have been shown to 
increase the intentions of  smokers 
to quit because of  their heightened 
knowledge of  the health effects of  
smoking.36 Health Canada has had 
the same graphic warning labels 
on tobacco products for about ten 
years but it has not yet adopted 
an eye disease related warning 
label for smoking despite hav-
ing one under consideration since 
2006 (see the Tobacco Labeling 
Resource Centre for current and 
test Canadian warning labels: www.
tobaccolabels.ca). In contrast, other 
countries37-38 have already adopted 
eye-related messages in their to-
bacco campaigns.
In this paper, we describe 
Canadian smokers’ knowledge of  
the link between tobacco use and 
blindness as well as the recommen-
dations of  Canadian optometrists 
and senior optometry students 
about warning graphic labels spe-
cific to eye disease.
Methods
Canadian Smokers’ Knowledge 
of Smoking Causing Blindness
Subsequent to institutional ethics 
clearance, we accessed data on  
Canadian smokers’ knowledge 
about the health impacts of  smok-
ing using the International Tobacco 
Control Policy Evaluation Project 
(ITC) Four Country Survey. It is 
a longitudinal cohort study con-
ducted approximately annually 
with adult smokers in Canada, the 
United States, the United Kingdom, 
and Australia. For the purposes 
of  this study, we focused on the 
Canadian data. The ITC Four 
Country survey began in 2002 and 
has included a measure of  respon-
dents’ knowledge of  smoking and 
blindness since the third survey in 
2004 (called Wave 3). Eligibility for 
the ITC Canada sample required 
participants to live in Canada, be 
at least 18-years-old, have smoked 
more than 100 cigarettes in their 
life and at least once in the pre-
vious 30 days, and be willing to 
complete the ITC Four Country 
phone survey. Further details about 
the ITC Four Country survey and 
methods have been published else-
where.39-41 This evaluation method 
has been found to provide a reli-
able indicator of  national smoking 
behavior trends. The ITC-4 survey 
question pertaining to smoking and 
blindness was worded, I am going 
to read you a list of  health effects and 
diseases that may or may not be caused 
by smoking cigarettes.  Based on what 
you know or believe, does smoking cause 
blindness?
1 axe d'optimisation
sur la surface avant
8 axes d'optimisation
sur la surface arrière
2 axes d'optimisation 
sur la surface arrière
1 optimization 
axis on the front
8 optimization 
axes on the back
2 optimization 
axes on the back
Indices
Power Range (Total Sphere)
Gamme de puissances (sphère totale)
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The response options were: ‘Yes’, 
‘No’, or ‘Don’t know’. The analysis in 
this paper is limited to respondents 
answering the blindness knowledge 
question for their first time. Since 
each wave (i.e., year) incorporates 
new participants to replenish those 
who have been lost to follow-up, 
there are new participants in each 
wave. Combining respondents from 
waves 3 to 7 (i.e., 2004 to 2008), 
provided a total weighted sample 
of  3,839 Canadian daily smok-
ers. Response data were calculated 
provincially (by count and percentage 
of  respondents); proportions were 
compared using 2-tailed z-tests with 
an alpha of  0.05 used for significance 
testing.
Perceptions of Eye-Related 
Graphic Warning Labels
Focus groups were conducted with 
optometry students and com-
munity optometrists.  The study 
occurred in the Waterloo Region 
of  southwestern Ontario, Canada 
in the summer of  2009.
Detailed descriptions of  recruit-
ment and sampling for this study 
have been published previously.42,43 
The potential participant pool 
included 51 practicing optometrists 
and 30 fourth-year optometry 
students (60 additional fourth-year 
students were away on external 
clinical placements).  Eighteen 
fourth-year optometry students  
(15 women, 3 men) were scheduled 
into three focus groups (S1, S2, 
and S3) and eleven optometrists 
(7 women, 4 men) were scheduled 
into two focus groups (O1 and 
O2). These optometrists had been 
practicing for approximately 20 
years, on average, with an individ-
ual range from 5 to over 30 years. 
All but one had graduated from 
the local Doctor of  Optometry 
program. The 29 participant identi-
ties were represented by numbers; 
for example, the seven members 
of  student focus group S1 were 
numbered S1-1 to S1-7, and the six 
members of  optometrist group O1 
were numbered O1-1 to O1-6.
The multi-disciplinary research 
team, which drew from optometry, 
nursing, and psychology, developed 
a two-phase interview. The first 
Category #1 #2 #3 #4
Eye Disease
(4 choices)
Vision 
Impact
(3 choices)
Information 
(3 choices)
WARNING 
SMOKING CAUSES BLINDNESS
Smoking causes permanent nerve 
damage to the inner eye which 
leads to blindness.
WARNING 
SMOKING CAUSES BLINDNESS
Smoking causes irreversible 
damage to the back of the 
eye. This is known as macular 
degeneration. Central vision is 
lost, leading to blindness.
WARNING 
SMOKING CAUSES BLINDNESS
Smoking is a major cause of blindness.  Smoking at least doubles 
your risk of losing your sight.  When you stop smoking, the risk 
decreases over time.
TABLE 1
Graphic Warning Label Features Discussed
Help Patients See Life In HD
HD
New PureVision®2 HD Contact Lenses Designed with High Defi nition™ Optics 
New PureVision®2 HD contact lenses provide outstanding vision with vibrant 
colours and clear, crisp vision all day. They are designed to reduce halos 
and glare in low light with innovative design advances to improve comfort 
and breathability. Now, help your patients see everything life 
has to offer with new PureVision®2 HD contact lenses.
® /TM denote trademarks 
of Bausch & Lomb Incorporated. 
© 2011 Bausch & Lomb Incorporated 
Call your B + L Sales Representative for more information, 
1 800 668 7510 or visit bausch.ca
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phase addressed attitudes, practices 
and training regarding smoking 
behavior and smoking cessation re-
ferrals in optometric practice. The 
second phase focused on collecting 
reactions about the design con-
tent for possible tobacco product 
warning labels that included mes-
sages about tobacco use and eye 
health. Focus group respondents 
were given colour print-outs of  
ten different graphic warning label 
features designed for the current 
study by the research team. Some 
designs used images from graphic 
warning labels already used in Aus-
tralia, New Zealand, and Iran. The 
ten warning labels addressed three 
categories: 1) ‘Eye Disease’ (four 
designs intended to communicate 
eye disease), 2) ‘Vision Impact’ 
(three designs aimed to communi-
cate the experience of  vision loss), 
and 3) ‘Text Information’ (three 
designs showed different text mes-
sages). The labels were designed to 
encourage discussion about what 
features or approaches the respon-
dents felt were important. Table 1 
shows the ten graphic label features 
discussed by the informants. Focus 
group facilitators (RDK & KM) 
were experienced in tobacco con-
trol research.  A research assistant 
(VZ) made field notes during the 
focus group discussions, which 
were audio-recorded and later tran-
scribed verbatim.
We followed an inductive 
qualitative framework approach44 
where data analysis informs theory.  
Consistent with a framework ap-
proach, reading the focus group 
transcripts allowed the members 
of  the research team to familiarize 
themselves with the data. Next, the 
team identified key issues, themes 
and concepts by which the data 
could be further examined.  The 
team identified five broad themes 
to examine: current practices, 
rationalizations, barriers, oppor-
tunities and graphic label recom-
mendations. Data excerpts that fit 
with the identified themes were 
indexed in the transcripts and then 
rearranged into thematic charts (a 
few exemplar excerpts are included 
in this paper). Finally, the thematic 
charts were examined with the 
goal of  finding associations and 
explanations for the findings; a 
process referred to by Bryman and 
Burgess44 as ‘mapping and interpre-
tation’.  Analysis of  the first four 
themes is reported elsewhere42-43; 
theme five, ‘graphic label recom-
mendations’, is reported herein.
Results & Discussion
Canadian Smokers’ Knowledge 
of Smoking Causing Blindness
Table 2 summarizes the provincial 
knowledge data among sampled 
smokers from Canada in the ITC 
Four Country phone survey be-
tween 2004 and 2008. The propor-
tion of  Canadian smokers that 
knew smoking can cause blindness 
was notably lower (14.2%) than 
those who discounted the link 
(69.6%). Knowledge of  this asso-
ciation among Quebec respondents 
(20.5%) was significantly higher 
than the rest of  Canada (z-score 
value 6.878, p<0.0001). Only two 
other provinces, Newfoundland 
PROVINCES NL PE NS NB QC ON MB SK AB BC Total
Blindness Yes Count 10 1 16 15 213 162 18 21 32 55 543
% 14.7% 5.3% 12.9% 14.3% 20.5% 11.5% 13.6% 16.4% 8.3% 13.2% 14.2%
No Count 48 16 87 69 681 1,016 94 82 294 279 2,666
% 70.6% 84.2% 70.2% 65.7% 65.7% 71.9% 71.2% 64.1% 76.0% 67.1% 69.6%
Don't  
Know
Count 10 2 21 21 143 236 20 25 61 82 621
% 14.7% 10.5% 16.9% 20.0% 13.8% 16.7% 15.2% 19.5% 15.8% 19.7% 16.2%
Total Count 68 19 124 105 1,037 1,414 132 128 387 416 3,830
% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100%
TABLE 2
Smokers’ Knowledge that Smoking Causes Blindness by Canadian Province
Bausch + Lomb Simplifies 
Ocular Vitamins
From the Global Leader 
in Ocular Vitamins*
For Patients at  
Risk of AMD
For Patients Diagnosed  
with AMD
Eye-Specific Formula AREDS-Based Formula
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and Labrador, and New Bruns-
wick, showed knowledge slightly 
above the national average. Health 
Canada’s website (www.hc-sc.gc.ca) 
provides an ‘Inventory of  Cana-
dian Tobacco Cessation Programs 
and Resources’ provided in each 
province and territory; in each 
jurisdiction there is a variety of  
tobacco prevention and cessation 
programs yet none of  these include 
any information or explicit content 
on eye diseases caused by smoking.  
At this point, we are unsure why 
knowledge of  the link between 
smoking and vision loss is higher 
in Quebec than any other province. 
Yet, even if  we focus on the prov-
ince with the highest knowledge, 
we are left with the reality that only 
1 in 5 smokers know about the link 
between smoking and blindness.  
More likely, 1 in 7, at best, know 
this information. Thus, Canadian 
optometrists can have an important 
role in improving patient education 
about the link between smoking 
and eye disease. These Canadian  
findings are comparable with 
measures of  American and UK 
smoker’s knowledge; however, less 
than that in Australia where social 
marketing has included the eye and 
nearly half  of  smokers were aware 
of  the link.45
 
Perceptions of Eye-Related 
Graphic Warning Labels
Analysis of  the focus group discus-
sions regarding the graphic warn-
ing labels revealed two sub-themes: 
1) Accurately Linking Smoking 
and Blindness, and 2) Framing 
Desirable Messages. Respondents 
thought that both the views of  
optometrists and the public should 
be considered ultimately in design-
ing a suitable eye-focused graphic 
warning label.
Both the optometrists and 
senior optometry students placed 
high importance on graphic warn-
ing labels that accurately linked 
smoking and blindness. Respon-
dents felt that these labels should  
TABLE 3 
Preferred Graphic Warning Labels Per Category
Label Category Preferred Label Content
Eye Disease Graphics
(4 choices)
Vision Impact Graphics
(3 choices)
Text Information
(3 choices)
WARNING – SMOKING CAUSES BLINDNESS
Smoking is a major cause of blindness. Smoking at least doubles your risk of losing 
your sight.  When you stop smoking, the risk decreases over time
.
TargeT  
SeaSonal allergic 
conjuncTiviTiS
with alrex® 
Treat the Signs and Symptoms
•  ALREX® treats the signs and symptoms of seasonal allergic conjunctivitis1
• Proven efficacy with an excellent safety profile1
•  Available in 5 mL bottles
ALREX® (loteprednol etabonate) Ophthalmic Solution 0.2% is indicated for temporary short-term relief of the signs and symptoms of seasonal 
allergic conjunctivitis.
Alrex® is for ophthalmic, short-term use only (up to 14 days). If Alrex® is used for 10 days or longer, intraocular pressure should be monitored. 
Alrex® is contraindicated in suspected or confirmed infections of the eye: viral diseases of the cornea and conjunctiva including epithelial herpes 
simplex keratitis (dendritic keratitis), vaccinia, and varicella; untreated ocular infection of the eye; mycobacterial infection of the eye and fungal 
diseases of ocular structures; hypersensitivity to this drug or any ingredient in the formulation or container, or to other corticosteroids. 
Reactions associated with ophthalmic steroids include elevated intraocular pressure, which may be associated with optic nerve damage, visual 
acuity and field defects, posterior subcapsular cataract formation, secondary ocular infection from pathogens including herpes simplex, and 
perforation of the globe where there is thinning of the cornea or sclera.
In clinical studies, adverse events related to loteprednol etabonate were generally mild to moderate, non-serious and did not interrupt continuation 
in the studies. The most frequent ocular event reported as related to therapy was increased IOP: 6% (77/1209) in patients receiving loteprednol 
etabonate, as compared to 3% (25/806) in the placebo treated patients.
Bausch & Lomb Canada Inc., Vaughan, ON L4K 4B4          
©2010 Bausch & Lomb Incorporated         ®Denotes trademark of Bausch & Lomb Incorporated or its affiliates
References: 1. ALREX Product Monograph, December 22, 2008    
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depict either common eye dis-
eases associated with smoking (e.g., 
age-related macular degeneration 
or cataract) or communicate the 
experience of  vision loss expected 
from these diseases (e.g., the impact 
of  central vision loss with ARMD). 
Table 3 shows the most preferred 
graphic warning label features in 
the categories of  ‘Eye Disease’, 
‘Vision Impact’ and ‘Text Infor-
mation’. It was very important to 
respondents that the graphic image 
be a plausible risk of  smoking; for 
example, respondents objected to 
one ‘Eye Disease Graphic’ that 
appeared more illustrative of  eye 
trauma than smoking. Optometrist 
O1-1, highlighted this concern, 
saying, “I think a lot of  people 
smoking are going to go, ‘Yeah, 
right, like that’s going to happen to 
my eye if  I smoke!  Like give me a 
break!’ ”.
Numerous respondents voiced 
a concern that a majority of  the 
public do not know enough about 
eyes, eye disease and the links to 
smoking; thus the graphic label 
must seem a plausible consequence 
of  smoking despite most viewers 
having a limited knowledge of  the 
eye and eye disease. The respon-
dents felt that most people could 
recognize an obviously diseased 
lung or heart but few would 
recognize a photo of  age-related 
macular degeneration or cataract. 
As O1-4 noted after looking at the 
four ‘Eye Disease Graphics’, “You 
know when a lay person looks at 
these pictures, half  of  the time they 
won’t recognize them”. In part, 
because of  this lack of  knowledge, 
more of  the respondents pre-
ferred graphic warning labels that 
(loteprednol etabonate ophthalmic suspension 0.2% w/v)
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hypoglycemics, so that a change in dose of the antidiabetic drugs may be necessitated. In high doses, glucocorticoids
also decrease the response to somatotropin. The usual doses of mineralocorticoids and large doses of some
glucocorticoids cause hypokalemia and may exaggerate the hypokalemic effects of thiazides and high-ceiling diuretics.
In combination with amphotericin-B, they also may cause hypokalemia. Glucocorticoids appear to enhance the
ulcerogenic effects of non-steroidal anti-inflammatory drugs. They decrease the plasma levels of salicylates, and
salicylism may occur on discontinuing steroids. Glucocorticoids may increase or decrease the effects of prothrombopenic
anticoagulants. Estrogens, phenobarbital, phenytoin and rifampin increase the metabolic clearance of adrenal steroids
and hence necessitate dose adjustments.
However, given the very low systemic exposure to loteprednol etabonate when using Alrex® as directed, these possible
effects are not likely. 
Immune
Cortisol and the synthetic analogs of cortisol have the capacity to prevent or suppress the development of the local
heat, redness, swelling, and tenderness by which inflammation is recognized. At the microscopic level, they inhibit not
only the early phenomena of the inflammatory process (edema, fibrin deposition, capillary dilation, migration of
leukocytes into the inflamed area, and phagocytic activity) but also the later manifestations, such as capillary
proliferation, fibroblast proliferation, deposition of collagen, and, still later, cicatrisation.
Clinical Trial Adverse Drug Reactions
Possibly or probably related adverse events from two Phase III studies are listed below:
One patient in the Alrex® group and one patient in the placebo group experienced increases in IOP of ≥10 mm Hg.
Among these, one in each group had an IOP increase of ≥15 mm Hg, reaching IOP values over 30 mm Hg.
In both studies, there were more patients with IOP increases of 6 to 9 mm Hg in the Alrex® group than in the placebo
group (see table below). In study A, among the patients with IOP increases of 6 to 9 mm Hg, four reached an IOP
value of 22 to 23 mm Hg, and one patient reached 29 mm Hg and was discontinued (clinically significant increase in
IOP). All these five patients were from the Alrex® groups.
Incidence of IOP increases of 6 to 9 mm Hg from baseline
(number of patients and percentages)
Due to the sample size for each arm of the two phase III studies in SAC, all events captured are greater than 1% of n.
SYMPTOMS AND TREATMENT OF OVERDOSAGE
For management of suspected accidental oral ingestion or drug overdose, consult your regional poison control centre.
No cases of overdose have been reported.
Full Product Monograph available for health professionals at: http://www.bausch.ca
© 2008 Bausch & Lomb Canada Incorporated.
Vaughan Ontario 
L4K 4B4
™/® Denote trademarks of Bausch & Lomb Incorporated or its affiliates.
Alrex® 0.2% Placebo
N = 133 N = 135
SPECIAL SENSES (EYE DISORDERS)
Intraocular Pressure
- elevation of 6 to 9mm Hg* 2% to 12%* 0% to 6%*
- elevation of ≥10mm Hg 1 (1%) 1 (1%)
Chemosis 6 (5%) 7 (5%)
Vision, Abnormal or Blurred 4 (3%) 5 (4%)
Burning/Stinging, on instillation 3 (2%) 6 (4%)
Itching Eye 3 (2%) 3 (2%)
Dry Eye 2 (2%) 4 (3%)
Burning/Stinging, not on instillation 2 (2%) 2 (1%)
Epiphora 1 (1%) 9 (7%)
Discharge 1 (1%) 3 (2%)
Foreign Body Sensation 1 (1%) 1 (1%)
Discomfort Eye 1 (1%) 0 (0%)
Injection 1 (1%) 0 (0%)
Eye Pain 1 (1%) 0 (0%)
Sticky Eye 0 (0%) 7 (5%)
Erythema Eyelids 0 (0%) 2 (1%)
Eye Disorder 0 (0%) 2 (1%)
BODY AS A WHOLE
Face Edema (Head) 1 (1%) 0 (0%)
Allergic Reaction 1 (1%) 0 (0%)
MUSCULOSKELETAL SYSTEM
Twitching 0 (0%) 1 (1%)
* for IOP increase of 6 to 9 mm Hg, please see below 
Duration of treatment
Day 7 Day 14 Day 28
Alrex®
Study-A 6 (9%) 6 (9%) 8 (12%)
Study-B 3 (5%) 1 (2%) 4 (6%)
Placebo
Study-A 0 (0%) 4 (6%) 1 (2%)
Study-B 0 (%) 0 (%) 0 (%)
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showed smoking-induced impacts 
on vision rather than the related 
ocular pathology.  As one opto-
metry student noted looking at the 
preferred ‘Vision Impact Graphic’ 
(Table 2), “You’re putting yourself  
in those eyes and saying, ‘Oh, my 
God, I won’t be able to see my 
loved ones’. And that hits home” 
(S3-4).  Respondents also preferred 
text that included direct language, 
stats and incentives about reduc-
ing risk. As S3-2 argued, “I think if  
you want people to stop smoking 
you should provide them with the 
facts.”
Respondents also placed a 
high priority on framing desirable 
messages. Interestingly, the op-
tometrists and optometry students 
believed that graphic warning labels 
are largely intended to motivate 
quitting through scare tactics but 
they would rather motivate quitting 
through education and empower-
ment. For example, it should be 
important to those who smoke 
to know how much their risk of  
blindness is lowered by tobacco 
cessation. Numerous respondents 
indicated that different strate-
gies were needed for youth (e.g., 
unable to drive a car) than seniors 
(e.g., unable to see grandchildren).  
Several respondents also felt that 
eye diseases seen predominantly in 
seniors (e.g., AMD, cataract) would 
not motivate youth to avoid or quit 
smoking and if  there was an age 
cohort where scare tactics might 
be successful, it was the youth. As 
O2-4 noted, “Your older group 
would appreciate macular degener-
ation but not if  you’re targeting the 
young ones… So, I think you need 
to have multiple messages”.
While optometrists may not 
have specific training in social 
judgment, message framing, and 
statistical heuristics deployed by 
health psychologists and public 
health experts, these focus group 
data show that optometrists have 
important ideas to contribute to 
this discussion. Many of  the infor-
mants in this study supported the 
idea of  having posters and other 
promotional materials in their 
practices, provided they judged the 
materials to be accurate, sensitive 
and suitable. Thus, if  the tobacco 
control community begins to use 
eye health related messaging, it will 
be important to develop messages 
with which eye care professionals 
feel comfortable.
Implications
Consistent with studies of  other 
countries, knowledge is low among 
Canadian smokers about the causal 
association of  smoking and blind-
ness. Further research is needed to 
identify the reasons for this limited 
knowledge; however, with, on aver-
age, only 1 in 7 Canadian smokers 
knowing about this link, there is 
a clear opportunity for increased 
patient education by optometrists, 
other healthcare practitioners and 
public health workers. Knowing 
both about the age at which smok-
ing often starts46 and its addictive 
qualities, optometrists should be 
routinely incorporating interview 
questions about smoking, starting 
with patients over 10 years of  age.  
Tobacco use assessment should 
include the onset, the amount 
(e.g., number of  cigarettes per day) 
and the type of  tobacco use (e.g., 
smoking, chew, snuff), the interest 
in quitting and past quit attempts.  
Tobacco dependence intervention 
by optometrists can help reduce 
the health consequences incurred 
with tobacco use. Toward this end, 
optometrists can contact their local 
public health department to learn 
more about tobacco cessation 
programs in their area and incorpo-
rate some of  this information into 
their patient counseling, includ-
ing contacts for the national and 
provincial quit lines.2 Like other 
healthcare providers, optometrists 
can facilitate higher quit rates 
among smokers who learn about 
its health effects and cessation 
strategies. The 29 optometry par-
ticipants in this study were clear in 
their conviction that optometrists 
should be at the table, helping to 
design effective educational tools 
linking smoking to blindness. The 
findings of  this preliminary study 
may help inform the development 
of  tobacco prevention and cessa-
tion tools and materials ultimately 
used by optometrists in their prac-
tices. Optometrists seem to want 
more of  their patients to see the 
causal association of  smoking and 
blindness, the ocular and systemic 
benefits of  tobacco cessation, and 
informative, motivating eye health 
messages about tobacco use.
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i The 2008 Canadian study found 
tobacco users included those who used 
cigars (2.6%), chewing tobacco and 
snuff  (0.5%), and pipes (0.4%).
ii  The national Smoker’s Helpline can 
be contacted via its web-site (http://
www.smokershelpline.ca) or phone line 
(1-877-513-5333).  Provincial quit lines 
are listed on the Health Canada web-
site (http://www.hc-sc.gc.ca), following 
the links: Home > Health Concerns > 
Tobacco > Quit Smoking > Quit Now 
> 1-800 Quit Lines).
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